APO IMA 400 (Imatinib mesylate 400 mg)
Pill imprint APO IMA 400 has been identified as Imatinib mesylate 400 mg.
Imatinib is used in the treatment of chronic myelogenous leukemia; gastrointestinal stromal tumor; chronic eosinophilic leukemia; dermatofibrosarcoma protuberans; acute lymphoblastic leukemia (and more), and belongs to the drug class BCR-ABL tyrosine kinase inhibitors. There is positive evidence of human fetal risk during pregnancy. Imatinib 400 mg is not a controlled substance under the Controlled Substance Act (CSA).
More about imatinib
- Other brands: Gleevec
Related treatment guides
Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Copyright 2017 Drugs.com, National Library of Medicine, Truven Health Analytics and Cerner Multum, Inc. All Rights Reserved.